2. Disease Areas
  3. Inflammation or Immune System Disease
  4. Digestive System Inflammation
  5. Periodontal Disease

Periodontal Disease

Periodontal disease is a serious bacterial infection that causes inflammation and destruction of the gums and supporting bone around the teeth, leading to progressive damage of the tooth-supporting apparatus. It begins as gingivitis—characterized by red, swollen gums that bleed easily—and can advance to periodontitis, resulting in gum recession, deep pockets, pus formation, and eventual tooth loss if untreated. Contributing factors include poor oral hygiene, genetic predisposition, and systemic conditions. The disease is chronic, often asymptomatic in early stages, but can lead to significant functional, aesthetic, and psychological consequences. Prevention relies on consistent oral hygiene, regular dental care, and early intervention. Treatment includes professional cleaning, antibiotics, and surgical procedures to restore damaged tissues, emphasizing the importance of timely detection and management.

Periodontal Disease (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W002879
    4-Hydroxyphenylboronic acid pinacol ester 269409-70-3 99.72%
    4-Hydroxyphenylboronic acid pinacol ester is a ROS-responsive component. 4-Hydroxyphenylboronic acid pinacol ester can structurally modify hyaluronic acid to prepare ROS-responsive intelligent nanocarriers and compound delivery systems. 4-Hydroxyphenylboronic acid pinacol ester endows hyaluronic acid-based nanocarriers with ROS responsiveness, enabling them to rapidly release the encapsulated Curcumin (HY-N0005) in the presence of reactive oxygen species. 4-Hydroxyphenylboronic acid pinacol ester is applicable to research related to periodontitis. 4-Hydroxyphenylboronic acid pinacol ester can also be used for the synthesis of boronic acid-modified resins.
    4-Hydroxyphenylboronic acid pinacol ester
  • HY-113440
    5-Methoxytryptophol 712-09-4 99.95%
    5-Methoxytryptophol is a 5-methoxyindole alcohol structurally homologous to Melatonin (HY-B0075). It is secreted by the mammalian pineal gland and exhibits an inverse circadian rhythm. 5-Methoxytryptophol regulates bone metabolism by activating the ERK1/2 pathway. It reduces the levels of pro-inflammatory cytokines TNF-α and IL-1β, as well as proteolytic enzymes MMP-1 and MMP-2, in serum and dental pulp tissues, thereby ameliorating acute pulpitis. 5-Methoxytryptophol induces rapid sleep in mice, while high doses cause respiratory depression and death. 5-Methoxytryptophol. 5-Methoxytryptophol can be used in studies related to acute pulpitis, hypnosis, and bone metabolism.
    5-Methoxytryptophol
  • HY-126675G
    AS2863619 (GMP) 2241300-51-4
    AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
    AS2863619 (GMP)
  • HY-182757
    Y1693 2812381-74-9 99.91%
    Y1693 is an orally active RANKL inhibitor with a Kd of 5.03 μM for hRANKL. Y1693 inhibits the activation of the downstream c-fos/NFATc1 signaling pathway by blocking its interaction with RANK. Y1693 significantly inhibits RANKL-induced osteoclast differentiation, F-actin ring formation and bone resorptive activity, while downregulating the mRNA and protein expressions of TRAP, cathepsin K, c-fos and NFATc1. Y1693 shows no obvious cytotoxicity to bone marrow-derived macrophages and osteoclast precursor cells, and exhibits favorable ADME properties. Y1693 improves ovariectomy-induced osteoporosis in mice and reverses ligation-induced periodontal alveolar bone loss. Y1693 is applicable to research related to osteoporosis and periodontal diseases.
    Y1693
  • HY-B0356G
    Ciprofloxacin (GMP) 85721-33-1
    Ciprofloxacin GMP is Ciprofloxacin (HY-B0356) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ciprofloxacin (Bay-09867) is an orally active, blood-brain barrier permeable fluoroquinolone antibacterial agent. Ciprofloxacin exerts bactericidal effects primarily by inhibiting topoisomerase II and IV. Ciprofloxacin inhibits the proliferation of human dental pulp stem cells and chondrocytes from young rats, and also activates the Akt signaling pathway and upregulates markers such as β-catenin and Nanog to maintain the morphological characteristics of stem cells. Ciprofloxacin induces significant neurotoxicity and tissue damage, including reducing serotonin and glutathione levels in the brain, inducing oxidative stress and depression-like behaviors, and causing articular cartilage damage. Ciprofloxacin can be applied to research related to infections of necrotic young permanent teeth and neurotoxicity.
    Ciprofloxacin (GMP)
  • HY-179514
    Gala-SR 3092129-97-7
    Gala-SR (Gala-SR1078) is an RORα agonist. Gala-SR ameliorates rhythm disorders by enhancing the amplitude of the circadian rhythm. Gala-SR can be used for the study of periodontitis.
    Gala-SR
  • HY-N17632
    Moracin G 73338-86-0
    Moracin G is a plant-derived kinase modulator and receptor ligand that forms stable bindings with multiple key proteins (AKT1, COX2 and Estrogen receptor 1) and competitively inhibits the activity of specific kinases. By binding to MELK to disrupt cell cycle regulation, Moracin G impairs the survival and proliferation of cancer cells, induces cancer cell apoptosis, and thereby exerts anti-tumor potential. Moracin G can be used in research related to periodontitis and breast cancer.
    Moracin G
  • HY-P2302
    Defensin HNP-3 human 136661-76-2
    Defensin HNP-3 human is an α-defensin stored in the azurophilic granules of human neutrophils. Defensin HNP-3 human exerts broad-spectrum bactericidal, antifungal and antiviral activities mainly by forming bacterial membrane pores, and acts as a chemoattractant for monocytes and T cells. Defensin HNP-3 human maintains epithelial integrity to support periodontal tissue homeostasis, and exerts concentration-dependent effects on epithelial cell proliferation, adhesion and bacterial adhesion. Defensin HNP-3 human targets solid tumors and leukemia by inducing single-strand DNA breaks and membrane permeabilization in tumor cells via electrostatic binding and pore formation. Defensin HNP-3 human is abundant in human tongue squamous cell carcinoma and neutrophils infiltrating oral squamous cell carcinoma. Defensin HNP-3 human can be applied to research related to periodontitis and human tongue squamous cell carcinoma.
    Defensin HNP-3 human